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Purpose of the study
AI266073 is a 48-week, randomized, open-label, multi-
center study with the primary objective of evaluating non-
inferiority of simplification of ART to efavirenz/emtricit-
abine/tenofovir DF (EFV/FTC/TDF) vs. continuation of
the same baseline regimen (SBR) unmodified.
Methods
Patients on stable ART with HIV-RNA (VL) <200 copies/
mL for ≥3 months were stratified by NNRTI- or PI-based
ART, and randomized (2:1) to switch to EFV/FTC/TDF or
continue SBR. The primary end-point was maintenance of
VL < 200 copies/mL at 48 weeks by time to loss of viro-
logic response (TLOVR) algorithm (intent-to-treat, non-
completers = failure [ITT, NC = F], Δ = 15%); efficacy was
also assessed by VL <50 copies/mL (TLOVR; ITT, NC = F),
pure virologic response (non-responders defined as two
consecutive VL ≥50 copies/mL or one VL ≥50 copies/mL
followed by study discontinuation; PVR – by Kaplan
Meier); and by last observation carried forward (LOCF)
analysis where early discontinuations for an adverse event
(AE) were considered failures.
Summary of results
300 treated patients (EFV/FTC/TDF 203, SBR 97) were
evaluated (prior PI/NNRTI 53%/47%). Treatment arms
were well balanced: 88% males; 29% blacks; mean age 43
years; median baseline CD4 516 cells/mm3; 96% had VL
<50 copies/mL. (Table 1.)
At 48 weeks, EFV/FTC/TDF was found to be non-inferior
to SBR. Similar virologic responses were also observed
between arms when analyzed by PI and NNRTI strata and
prior or no prior use of TDF. Overall discontinuation rates
for EFV/FTC/TDF vs. SBR were 11% vs. 12% (AE 5% vs.
1%; withdrawal of consent 2% vs. 7%). In the EFV/FTC/
TDF arm, one patient discontinued for virologic failure.
Overall, more nervous system symptoms were reported
for EFV/FTC/TDF vs. SBR (dizziness 11% vs. 1%, abnor-
mal dreams 7% vs. 0%); these occurred early, were gener-
ally transient, mild, and more common with prior PI-
based ART. At 48 weeks, estimated GFR (MDRD) was
unchanged from baseline in both arms (median <1 mL/
min/1.73 m2; p = 0.870); a greater decline in fasting trig-
lycerides was observed at 48 weeks with EFV/FTC/TDF vs.
SBR (median -20 vs. -3 mg/dL; p = 0.035) which was more
pronounced in prior PI patients.
Conclusion
High and comparable rates of virologic suppression were
maintained with EFV/FTC/TDF vs. SBR, regardless of type
of prior ART. The grade/frequency of AEs reported for
patients switched to EFV/FTC/TDF was consistent with
previous studies.
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VL Endpoint (copies/mL) EFV/FTC/TDF SBR Difference EFV/FTC/TDF – SBR (95% CI)
<200 by TLOVR 89% 88% 1.1% (-6.7%, 8.8%)
<50 by TLOVR 87% 85% 2.6% (-5.9%, 11.1%)
<50 by PVR 95% 86% 8.9% (-7.7%, 25.6%)
<50 by LOCF 94% 97% -3.3% (-8.3%, 2.7%)Page 2 of 2
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